Menu
Sign In Search Podcasts Charts People & Topics Add Podcast API Blog Pricing

Jessica Mendoza

đŸ‘€ Speaker
6211 total appearances

Appearances Over Time

Podcast Appearances

The Journal.
Readers Can’t Get Enough of BookTok. Publishers Are Cashing In.

So BookTok's legacy is likely to live on. That's especially true for readers, and in particular, those who love cowboy-werewolf romances and sexy fairy love stories. Penn says BookTok has given these readers more agency.

The Journal.
Readers Can’t Get Enough of BookTok. Publishers Are Cashing In.

So BookTok's legacy is likely to live on. That's especially true for readers, and in particular, those who love cowboy-werewolf romances and sexy fairy love stories. Penn says BookTok has given these readers more agency.

The Journal.
Readers Can’t Get Enough of BookTok. Publishers Are Cashing In.

So BookTok's legacy is likely to live on. That's especially true for readers, and in particular, those who love cowboy-werewolf romances and sexy fairy love stories. Penn says BookTok has given these readers more agency.

The Journal.
Readers Can’t Get Enough of BookTok. Publishers Are Cashing In.

It sounds like you think TikTok will have elastic effect on readers. the publishing industry.

The Journal.
Readers Can’t Get Enough of BookTok. Publishers Are Cashing In.

It sounds like you think TikTok will have elastic effect on readers. the publishing industry.

The Journal.
Readers Can’t Get Enough of BookTok. Publishers Are Cashing In.

It sounds like you think TikTok will have elastic effect on readers. the publishing industry.

The Journal.
Readers Can’t Get Enough of BookTok. Publishers Are Cashing In.

This episode was originally published in December. The Journal is a co-production of Spotify and The Wall Street Journal. Thanks for listening. We'll be back tomorrow with a new episode.

The Journal.
Readers Can’t Get Enough of BookTok. Publishers Are Cashing In.

This episode was originally published in December. The Journal is a co-production of Spotify and The Wall Street Journal. Thanks for listening. We'll be back tomorrow with a new episode.

The Journal.
Readers Can’t Get Enough of BookTok. Publishers Are Cashing In.

This episode was originally published in December. The Journal is a co-production of Spotify and The Wall Street Journal. Thanks for listening. We'll be back tomorrow with a new episode.

The Journal.
Lady Gaga, Low-Rise Jeans, and the Next Recession

New fears of a possible recession on the horizon, the Dow losing 876 points after falling.

The Journal.
Lady Gaga, Low-Rise Jeans, and the Next Recession

New fears of a possible recession on the horizon, the Dow losing 876 points after falling.

The Journal.
Lady Gaga, Low-Rise Jeans, and the Next Recession

New fears of a possible recession on the horizon, the Dow losing 876 points after falling.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

In the world of big pharma, this is the sound of liquid gold. An assembly line in Denmark fills glass vials with semaglutide. It's the active ingredient in the injectable drug that's become a bona fide cultural phenomenon. Where would you say Ozempic ranks in terms of successful drugs that you've covered?

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

In the world of big pharma, this is the sound of liquid gold. An assembly line in Denmark fills glass vials with semaglutide. It's the active ingredient in the injectable drug that's become a bona fide cultural phenomenon. Where would you say Ozempic ranks in terms of successful drugs that you've covered?

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

In the world of big pharma, this is the sound of liquid gold. An assembly line in Denmark fills glass vials with semaglutide. It's the active ingredient in the injectable drug that's become a bona fide cultural phenomenon. Where would you say Ozempic ranks in terms of successful drugs that you've covered?

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Tell me about the company behind this blockbuster drug.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Tell me about the company behind this blockbuster drug.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Tell me about the company behind this blockbuster drug.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Over the last decade, our colleague Pete Loftus has watched Novo Nordisk grow into a pharmaceutical juggernaut. Novo is one of the most valuable companies in Europe by stock market capitalization, thanks to the spectacular success of Ozempic and its sister drug, Wagovi.

The Journal.
Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?

Over the last decade, our colleague Pete Loftus has watched Novo Nordisk grow into a pharmaceutical juggernaut. Novo is one of the most valuable companies in Europe by stock market capitalization, thanks to the spectacular success of Ozempic and its sister drug, Wagovi.